Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Rating of “Buy” by Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $49.40.

SLP has been the topic of a number of recent research reports. BTIG Research dropped their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp lifted their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Finally, Stephens started coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock.

Simulations Plus Trading Up 2.0 %

Shares of NASDAQ SLP opened at $36.28 on Friday. Simulations Plus has a 12-month low of $24.00 and a 12-month high of $51.22. The stock’s fifty day simple moving average is $30.72 and its two-hundred day simple moving average is $32.47. The stock has a market capitalization of $728.87 million, a PE ratio of 90.70 and a beta of 0.82.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 19.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SLP. Barclays PLC increased its holdings in Simulations Plus by 390.6% in the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock worth $911,000 after buying an additional 22,669 shares during the period. Geode Capital Management LLC raised its holdings in shares of Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after purchasing an additional 18,924 shares during the last quarter. State Street Corp raised its holdings in shares of Simulations Plus by 4.7% during the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after purchasing an additional 28,953 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Simulations Plus by 106.0% during the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock valued at $1,517,000 after purchasing an additional 24,371 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after purchasing an additional 32,002 shares during the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.